Dapagliflozin and atrial fibrillation: elevated dosing to achieve class I antiarrhythmic effects?
Author:
Funder
Universitätsklinikum Hamburg-Eppendorf (UKE)
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s00395-024-01047-z.pdf
Reference16 articles.
1. Apostolakis S, Oeff M, Tebbe U, Fabritz L, Breithardt G, Kirchhof P (2013) Flecainide acetate for the treatment of atrial and ventricular arrhythmias. Expert Opin Pharmacother 14:347–357. https://doi.org/10.1517/14656566.2013.759212
2. Billing AM, Kim YC, Gullaksen S, Schrage B, Raabe J, Hutzfeldt A, Demir F, Kovalenko E, Lassé M, Dugourd A, Fallegger R, Klampe B, Jaegers J, Li Q, Kravtsova O, Crespo-Masip M, Palermo A, Fenton RA, Hoxha E, Blankenberg S, Kirchhof P, Huber TB, Laugesen E, Zeller T, Chrysopolou M, Saez-Rodriguez J, Magnussen C, Eschenhagen T, Staruschenko A, Siuzdak G, Poulsen PL, Schwab C, Cuello F, Vallon V, Rinschen MM (2023) Metabolic communication by SGLT2 inhibition. Circulation. https://doi.org/10.1161/circulationaha.123.065517
3. Carlson GF, Tou CKP, Parikh S, Birmingham BK, Butler K (2011) Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. Diabetes Ther 2:123–132. https://doi.org/10.1007/s13300-011-0003-2
4. Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, Myerburg RJ, Goldberger JJ (2021) Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Hear Rhythm 18:1098–1105. https://doi.org/10.1016/j.hrthm.2021.03.028
5. Gao J, Xue G, Zhan G, Wang X, Li J, Yang X, Xia Y (2022) Benefits of SGLT2 inhibitors in arrhythmias. Front Cardiovasc Med 9:1–13. https://doi.org/10.3389/fcvm.2022.1011429
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2;Basic Research in Cardiology;2024-07-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3